LG/Novartis Korea on joint marketing of fluvastatin.
Published: 2006-02-09 06:56:00
Updated: 2006-02-09 06:56:00
LG Life Science (President: Kim In-cheol) and Novartis Korea announced a joint marketing agreement on Feb. 6 for the distribution of fluvastatin, a cholesterol lowering drug under the trade names of Xylap XL by LG and Lescol XL by Novartis Korea.
Lescol XL was approved by U. S. FDA as a susta...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
